Acquired Long QT and Drug-Induced Torsades

Repolarization reserve is the concept that multiple K⁺ currents (I_Kr, I_Ks, I_K1) provide overlapping coverage for Phase 3 repolarization. If one current is partially impaired, the others compensate and the QT remains normal or near-normal.

Many individuals carry subclinical genetic variants that reduce one potassium current by 10–20% without producing a measurable QT prolongation at baseline. They have reduced reserve but normal function under routine conditions.

The problem emerges when a second or third insult stacks on top. A patient with a subclinical I_Kr variant receives a QT-prolonging antibiotic. Simultaneously, diuretic use drops their serum potassium to 3.2 mEq/L. A post-operative pause lengthens the RR interval. Each factor alone might be tolerable. Together, they overwhelm the remaining reserve, and the QT exceeds 550 ms.

This "multiple hit" model explains the clinical paradox: why the same drug causes Torsades in one patient but is harmless in thousands of others. The drug is rarely the sole cause. It is the final hit that breaks through an already-depleted reserve.

Nearly all drugs that cause QT prolongation do so by blocking I_Kr, the current carried by the hERG channel (encoded by KCNH2). This is the same channel mutated in congenital LQT2.

The hERG channel has an unusual structural feature: its inner cavity is larger and more accessible than most potassium channels. Aromatic amino acid residues line this cavity and create high-affinity binding sites for a wide range of drug molecules. Compounds that would never fit inside a typical K⁺ channel pore can lodge inside hERG and obstruct potassium flow.

This structural vulnerability is why drug-induced QT prolongation is a problem across pharmacological classes. Common offenders include:

• ●Antiarrhythmics: sotalol, dofetilide, ibutilide (deliberate I_Kr block for therapeutic effect)
• ●Antibiotics: erythromycin, clarithromycin, fluoroquinolones (moxifloxacin > levofloxacin > ciprofloxacin)
• ●Antipsychotics: haloperidol, ziprasidone, thioridazine
• ●Antiemetics: ondansetron (at high IV doses), droperidol

CredibleMeds (crediblemeds.org) maintains a continuously updated database classifying drugs by their TdP risk level. It is the standard clinical reference for QT-risk assessment before prescribing.

Hypokalemia reduces I_Kr conductance through a counterintuitive mechanism. The hERG channel conducts more efficiently when extracellular K⁺ is higher. When serum potassium falls, less current flows through I_Kr, and repolarization slows. This is why hypokalemia and hERG-blocking drugs are synergistic: both reduce the same current.

Hypomagnesemia destabilizes multiple potassium channels and increases calcium leak from the sarcoplasmic reticulum, promoting early afterdepolarizations. Magnesium also acts as a natural membrane stabilizer; its absence makes the cell more susceptible to oscillations during late repolarization.

Both must be aggressively corrected in any patient with QT prolongation. Target K⁺ of 4.5–5.0 mEq/L and Mg²⁺ above 2.0 mg/dL.

Torsades de Pointes does not start randomly. It follows a stereotyped initiation pattern called the short-long-short sequence.

First, a premature beat (short cycle) occurs. Then a compensatory pause follows (long cycle). During this long cycle, the action potential duration lengthens further because the cell has more time to recover and the QT stretches with the slower rate. The next sinus beat falls on a membrane that is still partially repolarizing. This creates the conditions for an early afterdepolarization (EAD), which fires a triggered beat at the peak of the T wave.

The clinical implication is direct: if you eliminate the pause, you eliminate the trigger. This is why overdrive pacing at 90–110 bpm is the definitive acute therapy for recurrent pause-dependent TdP. By preventing long cycles, you prevent the QT from stretching to dangerous lengths and suppress EAD formation.

When a patient develops Torsades de Pointes, the priorities are immediate and sequential.

Stop the offending drug. This seems obvious, but in practice the culprit may be one of several medications on a complex hospital formulary. Review every active medication against a QT-risk database.

IV magnesium (2–4 g bolus over 5–10 minutes) is first-line even if the serum magnesium is normal. Magnesium suppresses EAD formation by stabilizing membrane potential during late repolarization. It works within minutes.

Overdrive pacing is the definitive treatment for recurrent, pause-dependent TdP. A temporary transvenous pacing wire is set to pace the ventricle at 90–110 bpm. By eliminating long cycles, the QT shortens and EAD formation stops. The arrhythmia does not recur as long as pacing continues.

Isoproterenol serves as a pharmacological bridge to pacing when a wire cannot be placed immediately. Isoproterenol increases the sinus rate (shortening the QT) and enhances I_Ks through beta-adrenergic stimulation. It is not a long-term solution, but it can suppress TdP episodes while the team prepares for transvenous access.

Potassium repletion to 4.5–5.0 mEq/L restores I_Kr conductance. Even a modest rise from 3.5 to 4.5 can meaningfully shorten the QT.